SKYE · XBRL financial data
Skye Bioscience financial statements, every fiscal year
The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (SKYE's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Research and development | 1,944 | 2,931 | 6,012 | — | — | — |
| General and administrative | 4,345 | 4,916 | 6,095 | 7,852 | 17,726 | 15,802 |
| Total operating expenses | 6,289 | 7,848 | 18,312 | 34,735 | 30,193 | 58,164 |
| Operating income (loss) | (6,289) | (7,848) | (18,312) | (34,735) | (30,193) | (58,164) |
| Interest income | 0 | 0 | 19 | 100 | 3,029 | 1,884 |
| Interest expense | 706 | 769 | 665 | 906 | 749 | 0 |
| Other income (expense) | — | — | — | 0 | (2) | (1) |
| Income tax expense (benefit) | 2 | 2 | 7 | 4 | 10 | 5 |
| Net income (loss) | (6,561) | (8,522) | (19,482) | (37,645) | (26,567) | (55,925) |
| Earnings per share, basic‡ USD per share | (7.50) | (5.00) | (10.00) | (5.37) | (0.73) | (1.41) |
| Earnings per share, diluted‡ USD per share | (7.50) | (5.00) | (10.00) | (5.37) | (0.73) | (1.41) |
| Weighted average shares, basic‡ thousands of shares | 923 | 1,626 | 2,221 | 7,006 | 36,487 | 39,663 |
| Weighted average shares, diluted‡ thousands of shares | 926 | 1,626 | 2,221 | 7,006 | 36,487 | 39,663 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-250 stock split (September 2023); filings made before it reported them unadjusted.
- † Share count changed about 2x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (SKYE's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 2,469 | 8,983 | 1,245 | 1,256 | 68,416 | 5,882 |
| Short-term investments | — | — | — | — | 0 | 19,855 |
| Prepaid and other current assets | 190 | — | — | — | — | — |
| Total current assets | 2,664 | 9,612 | 8,944 | 11,651 | 70,827 | 27,094 |
| Property and equipment, net | 7 | 88 | 88 | 43 | 1,433 | 899 |
| Right-of-use asset | 0 | 147 | 71 | 238 | 450 | 267 |
| Total assets | 2,672 | 9,855 | 9,111 | 11,940 | 72,764 | 28,314 |
| Accounts payable | 364 | 898 | 1,670 | 1,156 | 569 | 2,033 |
| Accrued liabilities | 5 | — | — | — | — | — |
| Total current liabilities | 787 | 3,912 | 12,119 | 13,901 | 4,339 | 8,205 |
| Lease liability, non-current | 0 | 79 | 0 | 171 | 273 | 84 |
| Total liabilities | 2,221 | 3,991 | 12,119 | 14,072 | 4,612 | 8,289 |
| Accumulated deficit | (38,734) | (47,256) | (66,738) | (104,383) | (130,950) | (186,874) |
| Total stockholders' equity | 451 | 5,864 | (3,008) | (2,132) | 68,152 | 20,024 |
| Total liabilities and equity | 2,672 | 9,855 | 9,111 | 11,940 | 72,764 | 28,314 |
| Common shares outstanding (cover page)‡ thousands of shares | 1,400 | 1,984 | 3,886 | 28,063 | 30,975 | 33,379 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-250 stock split (September 2023); filings made before it reported them unadjusted.
- † Share count changed about 2x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (SKYE's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (6,561) | (8,522) | (19,482) | (37,645) | (26,567) | (55,925) |
| Stock-based compensation | 303 | 869 | 629 | 988 | 8,317 | 7,768 |
| Depreciation and amortization | — | — | — | 124 | 299 | 723 |
| Net cash from operating activities | (6,054) | (6,475) | (12,744) | (13,952) | (25,237) | (43,063) |
| Purchases of property and equipment | 7 | 91 | 28 | 13 | 1,604 | 6 |
| Net cash from investing activities | (7) | (91) | 5,214 | 6,596 | (246) | (19,500) |
| Proceeds from issuing common stock | 6,086 | 6,063 | 0 | 4,974 | 0 | — |
| Net cash from financing activities | 6,701 | 13,079 | (209) | 16,443 | 83,562 | 30 |
| Net change in cash | 639 | 6,514 | (7,738) | 9,088 | 58,079 | (62,533) |
- † Share count changed about 2x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Skye Bioscience | 8,068 | not reported | (7,122)* | 35.4M | 1.4 quarters | 10-QJun 30, 2026 |
| Agenus | 18,738 | 34,518 | (31,199)* | 45.0M | 0.6 quarters | 10-QJun 30, 2026 |
| Vistagen Therapeutics | 16,991 | not reported | (14,707) | 44.4M | 2.2 quarters | 10-QJun 30, 2026 |
| Kodiak Sciences | 125,903 | not reported | (46,238)* | 62.8M | 2.7 quarters | 10-QJun 30, 2026 |
| Voyager Therapeutics | 35,769 | 3,165 | (25,842)* | 61.6M | 4.5 quarters | 10-QJun 30, 2026 |
| Eledon Pharmaceuticals | 6,803 | not reported | (22,677)* | 81.3M | 3.9 quarters | 10-QJun 30, 2026 |
| Puma Biotechnology | 36,537 | 56,502 | 1,624* | 51.6M | — | 10-QJun 30, 2026 |
| Alector | 59,915 | 3,320 | (34,217)* | 111.7M | 5.1 quarters | 10-QJun 30, 2026 |
| Neurogene | 112,485 | not reported | (23,761)* | 20.0M | 9.5 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.